Index

Note: Page numbers with italicized b’s, f’s and t’s refer to boxes, figures, and tables, respectively.

abuse. See elder abuse
acetaminophen, 179
active life expectancy (ALE), 97
activities of daily living (ADLs), 4–10. See also frailty
assessment of, 4–7
in oncology, 7
in people with dementia, 5–7
in rehabilitation settings, 7
basic, 4, 5
instrumental, 4, 5
interventions, 7–10
for community-dwelling older adults, 8–9
for long-term care residents, 9
for older hospital inpatients, 7–8
Adalat (nifedipine), 31
adherence to medications, 39–40
advance directives, 181–3
adverse drug events (ADEs), 14–15
Aldomet (methyldopa), 29
Aldoril (methyldopa-hydrochlorothiazide), 29
aldosterone blockers, 60–61
Aleve (naproxen), 30
alpha-blockers, 35
alprazolam (Xanax), 28
Alzheimer’s dementia. See dementia
Alzheimer’s disease, 5
amiodarone (Cordarone), 30
Amyta (lubiprostone), 146
amitriptyline (Elavil), 28
amphetamine, 30–31
amyloid precursor protein (APP), 75–6
analgesics, 35–6
Android (methyltestosterone), 31
angiotensin-converting enzyme inhibitors, 60
angiotensin receptor antagonists, 60
anorexia, 33
anorexic agents, 30
anticolinergics, 29, 45
anticoagulants, 61
anticonvulsants, 87
antidepressants, 34, 86, 101–2
antihistamines, 29, 35
antimuscarinic drugs, 35, 132, 133–4
antiplatelets, 61
antipsychotics, 71, 85–6
antraspasmodics, 28
apnea, 49–51
apolipoprotein E4 (ApoE4), 76
aromatherapy, 84
asthmatics, 44
Atarax (hydroxyzine), 29
Ativan (lorazepam), 28
atrial fibrillation, 76
Avapro (naproxen), 30
azithromycin, 46
barbiturates, 30
Barthel Index, 6, 7
basic activities of daily living (BADLs), 4, 5
Beers Criteria, 15, 27
belladonna alkaloids, 29
Benadryl (diphenhydramine), 29
Betul (diclofenac), 29
benzodiazepines, 28–9, 35, 71, 181
beta-agonists, 44–5
beta-blockers, 35, 61
biofeedback, 151
bisacodyl (Dulcolax), 30, 146
bladder outflow obstruction, 32
blood clotting disorders, 32
botulinum toxin, 133
breathlessness, 179
Bristol stool chart, 143
bronchodilators, 45
“brown bag”, 26
B-type natriuretic peptide (BNP), 63
calcium, 121
calcium channel blockers, 19
carbamazepine, 87
cardiocerebrovascular disease dementia and, 76
depression and, 97
potentially inappropriate prescriptions, 34
Cardura (doxazosin), 31
Care Complexity Prediction Instrument (COMPRI), 8
cascarose (Soma), 28
cetirizine, 46–7
central nervous system medications for, 37
potentially inappropriate prescriptions, 34
Index

chlorazepate (Tranxene), 29t
chlor diazepoxide (Librium), 29t
chlor Diazepoxide- Amitriptyline (Libritrol), 28–9t
chlorpheniramine (Chlor-Trimeton), 29t
chlorpropamide (Diabinese), 29t, 35t
Chlor-Trimeton (chlorpheniramine), 29t
chloroxazone (Paraflex), 28t
cholesterol, 76
cholinesterase inhibitors, 81–2, 87
chronic obstructive pulmonary diseases (COPD), 33t, 35t, 44–6, 180–81
chronic wounds, 163
consumption, 140–51
Confusion Assessment Method (CAM), 65–72
computerized physician order entry (CPOE), 13, 14–15, 19
Confusion Assessment Method (CAM), 68t
constipation, 140–51
alarm symptoms, 143b
biofeedback for, 151
causes of, 141–2
colon care surgery for, 151
complications, 143–4
defined, 141
diagnosis of, 141
diseases associated with, 142t
drugs associated with, 142t
management algorithms for, 150f
nonpharmacological treatments of, 144–5

in patients on opioid analgesics, 149
pharmacological treatments of, 145–9
bulking agents, 145
emesis, 149
lubiprostone, 149
magnesium, 148
osmotic laxatives, 145–8
polyethylene glycol, 145–8
prokinetics, 148–9
sorbitol, 148
stimulants, 148
stool softeners, 145
t suppositories, 149
potentially inappropriate medication, 33t
prevalence of, 140
prevention of, 144
search strategy, 140–41
continuous positive airway pressure (CPAP), 49
Cordarone (amiodarone), 30t
Cornell Scale for Depression in Dementia (CSDD), 100
corticosteroids, 35t
cyclandelate (Cyclospasmol), 29–30t
cyclobenzaprine (Flexeril), 28t
Cyclospasmol (cyclandelate), 29–30t
cyproheptadine (Periactin), 29t
Cystosol (sorbitol), 146t
Dalmane (flurazepam), 28t
darifenacin, 133–4t
Darvon (propoxyphene), 28t
Daypro (oxaprozin), 30t
debridement, 157t
decubitus ulcers. See pressure ulcers
delirium, 65–72
defined, 65
vs. dementia, 66t
management strategy, 69–70, 71t
occurrence of, 65
postoperative, 66–71
prevention of, 69, 70t
risk factors, 66–71, 70t
screening for, 67–9
search strategy, 65–7
Delirium Observation Screening Scale (DOSS), 68
Delirium Rating Scale-Revised-98 (DRS-R-98), 68
dementia, 73–87
behavioral and psychological symptoms of, 83–7
capacity and, 80
caregiver burden and interventions in, 81
vs. delirium, 66t
depression and, 77
diet and, 77
driving safety and, 80–81
estimating risk for, 77
function assessment in, 5–7
interventions for, 83–7
interventions for cognitive/behavioral symptoms of, 74f
investigations, 79
mild cognitive impairment and, 77
nonpharmacological treatments, 84–5
aromatherapy, 84
cognitive stimulation, 84–5
environment for wanderings, 85
light therapy and melatonin, 84
massage and touch, 84
music therapy, 84
physical activity/exercise, 84
reality orientation, 84–5
reminiscence therapy, 85
snoezelen, 85
validation therapy, 85
prevalence of, 73–5
referral, 79
risk factors, 75–7
age, 75
cardiovascular, 76
education, 75
ethnicity, 75
gender, 75
genetic, 75–6
head injury, 76
lifestyle, 77
modifiable, 75t, 76–7
nonmodifiable, 75–6
screening for, 78–80
search strategy, 73–5
symptoms and interventions for, 74f
urinary incontinence and, 135–6
Demerol (meperidine), 30t
depression, 94–103
burden of, 94–5
causes of, 95
comorbidity, 95–7
defined, 94
dementia and, 77
diagnosis of, 98
diagnostic criteria for, 94
flow chart for diagnosis and management of, 96f
patient health questionnaire-9, 99r, 100
potentially inappropriate medication, 33t
prevalence of, 95
prognosis, 97–8
risk factors, 95
search strategy, 98
treatment of, 100–102
antidepressants, 101–2
electroconvulsive therapy, 102
talking therapies, 101
underdiagnosis of, 98–100
desicated thyroid, 31t
detrusor hyperactivity with impaired contractility (DHIC), 129
dexchlorpheniramine (Polaramine), 29t
diabetes, 76–7
Diabinese (chlorpropamide), 29t
diazepam (Valium), 29t
dicyclomine (Bentyl), 29t
digoxin (Lanoxin), 29t
diazepam (Valium), 29t
diagnosis, 2
diabetes, 76–7
Diabinese (chlorpropamide), 29t
diazepam (Valium), 29t
dicyclomine (Bentyl), 29t
digoxin (Lanoxin), 29t
diazepam (Valium), 29t
diagnosis, 2
Index

heart failure (Continued)
  preserved ejection fraction, 62
  statins, 61–2
potentially inappropriate medication, 32r
search strategy, 58–9
telemonitoring, 63
home-visit programs, 9
Hospital Admission Risk Profile (HARP), 8
Hospital Anxiety and Depression Scale (HAD), 99
hynperea A, 83
Hyd ergine (ergot mesyloids), 29r
hydromorphone, 177
Hylorel (guanadrel), 30
hydroxyzine, 29
hydromorphone, 177
Hydergine (ergot mesyloids), 29
huperzine A, 83
Hospital Anxiety and Depression Scale (HAD), 99
Hospital Admission Risk Profile (HARP), 8
home-visit programs, 9
Identification of Seniors at Risk (ISAR), 8
instrumental activities of daily living (IADLs), 4, 5r, 6
interpersonal therapy, 101
Katz index, 5
Isomel (guanethidine), 30
Isoxsuprine (Vasodilan), 31
Karnofsky Performance Scale (KPS), 7
Katz index, 5
ketorolac (Toradol), 30r
lactulose, 146
Lanoxin (digoxin), 29
Lawton Brody Instrumental Activities of Daily Living Scale, 5, 6r
Lawton Brody Physical Self-Maintenance Scale (PSMS), 5
laxatives, 30r, 145–8
Legionella pneumophila, 46
Levon (hyosycamine), 29r
Levsinex (hyosycamine), 29r
Librax (clidinium-chlordiazepoxide), 29r
Librium (chlordiazepoxide), 29r
light therapy, 84
Limbitrol (chlordiazepoxide-amitriptyline), 28–9r
long-acting beta-agonists (LABA), 45
lorazepam (Ativan), 28r
lower urinary tract, 124–6
lubiprostone, 146r, 149
lung cancer, 49–51
nonsmall-cell lung carcinoma, 50
risk factors, 49
small-cell, 50
Macrodantin (nitrofurantoin), 31r
magnesium citrate, 146r
magnesium hydroxide, 146r
malnutrition, 33r
massage, 84
Medication Appropriateness Index (MAI), 27
Medication Appropriateness Index (MAI), 27
Medication Appropriateness Index (MAI), 27
medication prescribing. See prescribing medication reconciliation, 26
melatonin, 84
Mellaril (thioridazine), 31r
mementine, 82, 87
Memorial Delirium Assessment Scale (MDAS), 68
meperidine (Demerol), 30r, 178
meprobamate, 28r
mesoridazine (Serentil), 31r
Metamucil (psyllium), 146
mesoridazine (Serentil), 31r
methylcellulose, 146
methyltestosterone, 31
Methadone (Dilaudid), 29r
methylcellulose, 146
methyltestosterone, 31r
mild cognitive impairment (MCI), 5–6, 77, 97
Miltown (meprobamate), 28r
mineral oil, 31
Mirtazapine, 28
Mini-Cog, 78
Mini-Mental State Examination (MMSE), 68, 78r
Minalax (polyethylene glycol), 146r
mixed urinary incontinence, 127r, 131r
monoamine oxidase inhibitors (MAOIs), 101–2
Montreal Cognitive Assessment (MoCA), 78r, 79
morphine, 177
multisensory stimulation, 85
muscle relaxants, 28r
musculoskeletal system medications for, 37r
potentially inappropriate prescriptions, 35r
music therapy, 84
Mycobacterium tuberculosis, 47
Naprosyn (naproxen), 30r
naproxen, 30r
Neoloid, 30r
neuroleptic drugs, 35r
neuropathic pain, 178–9
nifedipine, 31r
nitrofurantoin (Macrodantin), 31r
nocturnal urinary incontinence, 127r, 131r
nonsmall-cell lung carcinoma (NSCLC), 50
non-steroidal anti-inflammatory drugs (NSAIDs), 30r, 35r, 178
Norflex (orphenadrine), 30r
Norse (disopyramide), 29r
Nursing Delirium Screening Scale (Nu-DESC), 68
nutrition, 157r, 160–61
obesity, 33r
obstructive sleep apnea (OA), 48–9
olanzapine, 71
oncology, functional assessment in, 7
oupates, 35r
opioid analogues, 149, 177–8, 179r
orphenadrine (Norflex), 30r
osmotic laxatives, 145–8
osteoarthritis, 178
osteoporosis, 117–22
calcium for, 121
exercises and, 121
guidelines, 118–20r
pharmacologic therapy for, 121–2
screening for, 121
vitamin D for, 121
overflow urinary incontinence, 127r, 131r
oxyprozir (Daypro), 30r
oxazepam (Serax), 28r
Oxford Centre for Evidence-Based Medicine (CEBM), 14
oxbyutin, 28r, 133–4r
oxygen therapy, 180–81
pain, 177–9
management of, 177–8
medications, 178–9
neuropathic, 178–9
prevalence of, 177
relief of, 177
treatments for, 179r
Paraflex (chloroxazone), 28r
Parkinson disease, 32r
Patient Health Questionnaire-9 (PHQ-9), 99r, 100
Paxipam (halazepam), 29r
pentazocine (Talwin), 28r
potentially inappropriate medications for, 37r
prescriptions, 35r
potentially inappropriate
potentially inappropriate
potentially inappropriate
Index

performance status (PS), 7
Periactin (cyproheptadine), 29t
phenolphazene-amiptirtipyline (Triavil), 28t
Persantine (diprydamole), 29t
Phenergan (promethazine), 29t
phentobarbital, 30t
physical abuse, 167–8
physical neglect, 168–9
Physical Self-Maintenance Scale (PSMS), 6t
piroxicam (Foldene), 30t
pneumonia, 46–7
Polaramine (deschlorpheniramine), 29t
polyethylene glycol, 145–8
polypharmacy, 26, 36–8
polypropylene, 145
polycarbophil, 146
pneumonia, 46–7
piroxicam (Feldene), 30
Phenergan (promethazine), 29
Persantine (nifedipine), 31
Pro-Banthine (propantheline), 29
Procardia (nifedipine), 31t
prokinetics, 147
Prozac (fluoxetine), 30t
prucalopride, 147t
psychodynamic therapy, 101
psychological abuse, 169
psychotropical drugs, 34t
psyllium, 146t
quazepam (Doral), 29t
randomized controlled trials (RCTs), 23–6
reality orientation therapy, 84–5
recombinant human platelet deprived factor, 149
rehabilitation, function assessment in, 7
reminiscence therapy, 85
repositioning, 157t, 159–60
reserpine, 29t
respiratory diseases, 43–51
asthma, 44
chronic obstructive pulmonary diseases, 44–6
lung cancer, 49–51
medications for, 37t
obstructive sleep apnea, 48–9
pneumonia, 46–7
potentially inappropriate prescriptions, 35t
search strategy, 43–4
tuberculosis, 47–8
Tigan (trimethobenzamide), 28t
ticagrelor, 30
Ticlid (ticlopidine), 30
Tigan (trimethobenzamide), 28t
tolterodine, 133–4
tricyclic antidepressants (TCAs), 34t
triazolam (Halcion), 29t
trazodone, 86
Triavil (perphenazine-amitriptyline), 28t
triazolam (Halcion), 29t
tricyclic antidepressants (TCAs), 34t
101–2
trimethobenzamide (Tigan), 28
triptorelin, 133–4t
Toradol (ketorolac), 30t
total life expectancy (TLE), 97
triamcinolone, 178, 179
Tramoxene (clorazapate), 29t
trazodone, 86
Triavil (perphenazine-amitriptyline), 28t
triazolam (Halcion), 29t
tricyclic antidepressants (TCAs), 34t,
101–2
trimethobenzamide (Tigan), 28t
triptorelin, 133–4t
tuberculosis, 47–8
tuberculosis, skin.
ulcers, skin. See pressure ulcers
urge urinary incontinence, 127t, 131t
urinary incontinence, 124–37
aging and, 124–6
behavioral interventions, 130–32
bladder training, 132
lifestyle interventions, 130
pelvic floor muscle training, 130–32
bulking agents for, 132
dementia and, 135–6
history, 128
investigations, 129
in long-term care residents, 135–6
medical devices for, 132
medications causing, 126t
models of care, 129
Index

urinary incontinence (Continued)
pharmacologic management, 132–5
physical examination, 128–9
pressure ulcers and, 159–60
prevalence of, 124
surgical management of, 135
treatment of, 129–35
types of, 127r, 131r
urinary tract, lower, 124–6

vacuum therapy, 161
validation therapy, 85
Valium (diazepam), 29t
valproic acid derivatives, 87
Vascular Cognitive Impairment (VCI), 6
Vasodilan (isosuprine), 31r
vasodilator drugs, 35t
violation of personal rights, 169

Virilon (methyltestosterone), 31t
Vistaril (hydroxyzine), 29t
vitamin D, 121
warfarin, 34t, 37t
wound, chronic, 162. See also pressure ulcers
Xanax (alprazolam), 28t